OMP-18R5 (vantictumab) is a monoclonal antibody aimed at inhibiting Fzd receptors and blocking the activation of the canonical WNT signalling in multiple tumour types, such as in CRC, BC, and pancreatic cancer (PC). The gene discussed is OMP; the disease is neoplasm.